N-三氮唑基噁唑烷酮类衍生物合成及抗肿瘤活性研究
收稿日期: 2017-02-06
修回日期: 2017-03-27
网络出版日期: 2017-05-02
基金资助
川大-泸州战略合作（No.2013CDLZ-S18）和NIMHD-RCMI（No.5G12MD007595）资助项目.
Synthesis and Antitumor Activity of N-Triazol-5-yl-oxazolidin-4-one Derivatives
Received date: 2017-02-06
Revised date: 2017-03-27
Online published: 2017-05-02
Supported by
Project supported by the Sichuan University-Lu Zhou Strategic Cooperation Projects (No. 2013CDLZ-S18), the NIH RCMI Program at Xavier University of Louisiana through Grant (No. 2G12MD007595-07).
以苯甲醛衍生物为起始物，经多步反应合成了15个未见文献报道的N-三氮唑基噁唑烷酮类衍生物.探索发现N-碘代丁二酰亚胺（NIS）以较高产率促进合成过程中的关键反应-分子内胺化反应，此反应为分子内构建氮杂环提供了新的方法.细胞毒活性测试表明，化合物6a、6b和6c对人乳腺癌细胞MDA-MB-231，6a、6b和6d对宫颈癌细胞HeLa有一定的抑制活性.
关键词： N-三氮唑基噁唑烷酮; N-碘代丁二酰亚胺; 分子内胺化反应; 抗肿瘤活性
罗睿 , 郭山春 , 郑时龙 , 王光迪 , 包旭 , 何菱 . N-三氮唑基噁唑烷酮类衍生物合成及抗肿瘤活性研究[J]. 有机化学, 2017 , 37(9) : 2435 -2441 . DOI: 10.6023/cjoc201701053
Fifteen novel N-triazol-5-yl-oxazolidin-4-ones were synthesized through a few of steps from the benzaldehydes. It was found that N-iodosuccinimide (NIS) can promote intramolecular amination reaction which is the key step of the syntheses, which will be used as new method for the intramolecular formation of nitrogen-containing heterocycles. Part of the compounds were evaluated for their anticancer activity. Among them, compounds 6a, 6b and 6c showed moderate antiprolifiration activity toward human breast cancer cells MDA-MB-231 cell lines, while the mild activity of 6a, 6b and 6d against human cervical cancer HeLa cell lines was confirmed in vitro assay.
[1] Chen, W.-Q.; Zheng, R.-S.; Baade, P. D.; Zhang, S.-W.; Zeng, H.-M.; Bray, F.; Jemal, A.; Yu, X.-Q.; He, J. Ca-Cancer J. Clin. 2016, 66, 115.
[2] Boschelli, D. H.; Connor, D. T.; Bornemeier, D. A.; Dyer, R. D.; Kennedy, A.; Kuipers, P. J.; Okonkwo, G. C.; Schrier, D. J.; Wright, C. D. J. Med. Chem. 1993, 36, 1802.
[3] Wang, Y.; Zhou, C.-H. Sci. Sin. Chim. 2011, 41, 1429(in Chinese). (王艳, 周成合, 中国科学:化学, 2011, 41, 1429.)
[4] Wang, C.-J.; Cao, Q.-P.; Yang, H.; Song, P.-P.; Xue, D.-Q.; Cui, F.; Gu, Y.-F.; Zhang, X.-S.; Tian, Y.-N.; Zhang, Q.-R.; Liu, H.-M. Chin. J. Org. Chem. 2016, 36, 1626(in Chinese). (王超杰, 曹钦坡, 杨慧, 宋攀攀, 薛登启, 崔飞, 顾一飞, 张孝松, 田亚楠, 张秋荣, 刘宏民, 有机化学, 2016, 36, 1626.)
[5] Dai, H.; Liu, J.-B.; Tao, W.-F.; Miao, W.-K.; Fang, J.-X.; Wang, Q.-M. Chin. J. Org. Chem. 2016, 36, 393(in Chinese). (戴红, 刘建兵, 陶伟峰, 苗文科, 方建新, 汪清民, 有机化学, 2016, 36, 393.)
[6] Wang, B.-L.; Shi, Y.-X.; Zhan, Y.-Z.; Zhang, L.-Y.; Zhang, Y.; Wang, L.-Z.; Zhang, X.; Li, Y.-H.; Li, Z.-M.; Li, B.-J. Chin. J. Chem. 2015, 33, 1124.
[7] Goss, P. E.; Strasser, K. J. Clin. Oncol. 2001, 19, 881.
[8] Gershanovich, M.; Chaudri, H. A.; Campos, D.; Lurie, H.; Bonaventura, A.; Jeffrey, M.; Buzzi, F.; Bodrogi, I.; Ludwig, H.; Reichardt, P.; O'Higgins, N.; Romieu, G.; Friederich, P.; Lassus, M. Ann. Oncol. 1998, 9, 639.
[9] Diekema, D. J.; Jones. R. N. Drugs 2000, 59, 7.
[10] Moellering, R. C. Ann. Intern. Med. 2003, 138, 135.
[11] Yin, P.; Ma, W.-B.; Chen, Y.; Huang, W.-C.; Deng, Y.; He. L. Org. Lett. 2009, 11, 5482.
[12] He, L.; Deng, Y.-X.; Li, J.-L. CN 102850337, 2013[Chem. Abstr. 2013, 158, 187510].
[13] Gu, L.-H.; Wang, P.; Zhong, Q.; Deng, Y.-X.; Xie, J.-P.; Liu, F.; Xiao, F.; Zheng, S.-L.; Chen, Y.; Wang, G.-D.; He, L. RSC Adv. 2017, 7, 9412.
[14] Ma, W.-B.; Li, S.-N.; Zhou, Z.-H.; Shen, H.-S.; Li, X.; Sun, Q.; He, L.; Xue, Y. Eur. J. Org. Chem. 2012, 1554.
[15] Zhao, L.-M.; Ma, F.-Y.; Jin, H.-S.; Zheng, S.-L.; Zhong, Q.; Wang, G.-D. Eur. J. Med. Chem. 2015, 102, 303.
[16] Li, X.; Zheng, S.-L.; Li, X.; Li, J.-L.; Qiang, O.; Liu, R.; L. He. Eur. J. Med. Chem. 2012, 54, 42.
/
| 〈 |
|
〉 |
